Microwave Ablation Treatment for Low-Risk Papillary Thyroid Microcarcinoma Evaluated by Contrast-Enhanced Ultrasound and Genetic Testing A Prospective Observational Study

What this Trial Is About

Researchers are evaluating the effectiveness and prognosis of microwave ablation therapy for treating papillary thyroid microcarcinoma PTMC, a common type of thyroid cancer with a diameter of 10 mm or less. PTMC is typically low-risk with mild behavior and good survival rates, but surgery, the usual treatment, can affect thyroid function and quality of life. This study also examines the use of contrast-enhanced ultrasound combined with genetic and molecular diagnostics to better assess treatment outcomes and assist clinical decisions. The study observes patients aged 18 to 70 with low-risk PTMC who have a single small lesion without metastasis or extrathyroidal extension. Participants undergo fine-needle aspiration and a panel test of 88 genes related to thyroid cancer before choosing either microwave ablation therapy or surgical resection. Contrast-enhanced ultrasound uses safe contrast agents like SonoVue to provide clearer imaging, helping to evaluate the treatments effectiveness over time. Participants will be monitored at multiple intervals after treatment, including 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months post-operation. During these visits, ultrasound imaging and genetic assessments will be performed to track treatment response and prognosis. The study aims to gather detailed data on the safety and outcomes of microwave ablation compared to surgery, supporting improved treatment choices for patients with PTMC.

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study